13,14-Dihydro-15-keto prostaglandin D2

13,14-Dihydro-15-keto prostaglandin D2 (DK-PGD2; 15-Oxo-13,14-dihydro-PGD2; 13,14-Dihydro-15-keto-PGD2) is a metabolite of Prostaglandin D2 (HY-101988) and acts as a CRTH2 agonist. 13,14-Dihydro-15-keto-prostaglandin D2 exhibits binding activity to CRTH2, induces cellular calcium signaling flux, and mediates eosinophilia in vivo. 13,14-Dihydro-15-keto-prostaglandin D2 activates the CRTH2 receptor, triggering G_i-dependent intracellular calcium mobilization and promoting the migration and recruitment of leukocytes from bone marrow to peripheral blood in vivo. 13,14-Dihydro-15-keto prostaglandin D2 is used in research on inflammation-related diseases, such as bronchial asthma^[1][2][3][4]. In Vitro:13,14‑Dihydro‑15‑keto‑prostaglandin D2 (DK-PGD₂) is a high-affinity ligand for rat, mouse, and human CRTH2 with IC₅₀ values of 9.4 nM, 6.1 nM, and 18.1 nM, respectively; this compound induces Ca²⁺ mobilization in CRTH2-transfected cells of the above three species in a PTX-sensitive manner, with corresponding EC₅₀ values of 90 nM, 40 nM, and 4.9 nM^[1].

13,14‑Dihydro‑15‑keto‑prostaglandin D2 is the major metabolite of Prostaglandin D2 formed in the isolated perfused rat lung^[2].
13,14‑Dihydro‑15‑keto‑prostaglandin D2 is a subsequent metabolite of 15‑keto‑PGD2; purified PGD2 dehydrogenase from porcine brain converts PGD2 to 15‑keto‑PGD2^[3].

13,14-Dihydro-15-keto-prostaglandin D2 (DK-PGD₂) (5-10 µM; 48 h) induces DP2 protein expression in a dose-dependent manner in colon cancer cell lines^[4].
13,14‑Dihydro‑15‑keto‑prostaglandin D2 (4 μM) induces calcium signaling in HT-29 cells, confirming its role as a DP2 agonist^[4].
13,14‑Dihydro‑15‑keto‑prostaglandin D2 (10 µM; 24-72 h) stimulates the proliferation and migration of HT-29 and Caco-2 cells^[4].
13,14-Dihydro-15-keto-prostaglandin D2 (10 µM; 48 h) stimulates the expression of p-ERK1/2, VEGF, and HIF-1α in HT-29 and Caco-2 cells^[4]. In Vivo:13,14‑Dihydro‑15‑keto‑prostaglandin D2 (DK-PGD₂) (100-300 μg/animal; i.v.) selectively activates CRTH2 and induces dose- and time-dependent recruitment of bone marrow leukocytes in rats^[1].
13,14‑Dihydro‑15‑keto‑prostaglandin D2 (DK-PGD₂) (10 μM; microinjection; pretreatment for 48 h) significantly enhances the metastatic capacity of HT‑29 colon cancer cells in a zebrafish xenograft model; after injection of tumor cells pretreated with this compound into zebrafish embryos, metastatic cells are observed in 30 out of 34 embryos^[4].